TWiV 1110: Clinical update with Dr. Daniel Griffin

This Week in Virology

In his weekly clinical update, Dr. Griffin begins with discussing if the antibiotic neomycin is really a pan-antiviral countermeasure, then reviews the recent statistics on SARS-CoV-2 infection before deep diving into if shedding and the rapid antigen test results correlate, the guidelines for spring administration of COVID vaccines boosters, whether COVID booster associates with the long COVID prevalence, discusses the emergency use application of a pre-exposure prophylactic, revised guidelines for how to treat respiratory viral infection guidelines by the CDC, the caveats for improper use of antibiotics to treat SARS-CoV-2 (a viral infection), continues to dispel the myth of viral rebound, when to use steroids and the benefits of convalescent plasma, what do when healthcare workers succumb to SARS-CoV-2 infection, if administration of an anti-immunoglobulin E monoclonal antibody can be used for COVID-19 treatment, if inhibiting T-cell activation will reduce secretion and production of inflammatory cytokines including IL-6, if changes in the gut microbiome associate with post -acute COVID-19 syndrome, and the pulmonary and neurologic determinants of long COVID-19 such as the presence of neurofilament light chain in plasma. For more information about this body of work, listen to TWiV 1088.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• Intranasal antibiotic evokes antiviral response (PNAS)
• COVID-19 national trend (CDC)
• COVID-19 deaths (CDC)
• SARS-CoV-2 shedding vs rapid antigen test performance (MMWR)
• Spring vaccineadvice (CIDRAP)
• Older adult spring booster available (CDC)
• Advisory committee for immunization practices slides (CDC)
• Advisory committee for immunization practices spring 2024 COVID-19 boosters (CDC)
• COVID-19 booster take: cross-sectional study (Vaccine)
• EUA for pemgarda (FDA)
• CDC Quarantine guidelines (CDC)
• NIH COVID-19 treatment guidelines (NIH)
• Infectious Disease Society guidelines for treatment and management (IDSociety)
• Overuse ofantibiotics for COVID-19: a viral disease (European Society of Clinical Microbiology and Infectious Diseases)
• Can you believe that antibiotics are ineffective against a viral illness (NKT Institute)
• Molnupiravir safety and efficacy (JMV)
• Convalescent plasma recommendation for immunocompromised (IDSociety)
• Outpatient treatment with concomitant vaccine-boosted convalescent plasma (mBio)
• Updated respiratory virus guidances (CDC)
• What do when your heathcare provider is infected with SARS-CoV-2 (CDC)
• Managing healthcare staffing shortages (CDC)
• Steroids,dexamethasone at the right time (OFID)
• Anticoagulation guidelines (hematology.org)
• Immunologic antiviral therapy with omalizumab (OFID)
• Abatacept pharmacokinetics and exposure response (JAMA Network Open)
• Long COVID evidence based review TWiV shout out (TWiV 1088)
• Gut microbiome and post-acute COVID-19 syndrome, ugh? (Cell Host and Microbe)
• Pulmonary long COVID (JCI Insight)
• Neurofilament light chain in long COVID019 neurocognitive symptoms (Molecular Psychiatry)
• Contribute to our Floating Doctors fundraiser
• Letters read on TWiV 1110
• Dr. Griffin’s COVID treatment summary (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to [e-mail]